All In Biotech

Drug Trial Radar · NCT05109390

A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults

A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adult Subjects

Last checked: Nov 20, 2026Latest source record: Nov 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Jul 27, 2018

Primary completion

Oct 17, 2018

Study completion Oct 17, 2018

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Achillion, a wholly owned subsidiary of Alexion
First posted
Nov 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This was a 3-part study with each part being an open-label, fixed-sequence, 2-period study in healthy adult participants.

Conditions

  • Healthy

Interventions

  • DanicopanDrug

    Oral tablet.

  • CyclosporineDrug

    Oral capsule.

  • TacrolimusDrug

    Oral capsule.

  • Calcium CarbonateDrug

    Chewable tablet.

  • Aluminum/Magnesium Hydroxide/SimethiconeDrug

    Chewable tablet.

  • OmeprazoleDrug

    Oral, delayed-release capsule.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Cyclosporine Maximum Observed Concentration (Cmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 72 hours postdose
  2. Part 1: Cyclosporine Time To Reach The Maximum Observed Concentration (Tmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 72 hours postdose
  3. Part 1: Cyclosporine Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 72 hours postdose
  4. Part 2: Tacrolimus Cmax Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 144 hours postdose
  5. Part 2: Tacrolimus Tmax Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 144 hours postdose
  6. Part 2: Tacrolimus AUC0-inf Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 144 hours postdose
  7. Part 3: Steady-state Omeprazole Cmax Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 24 hours postdose
  8. Part 3: Steady-state Omeprazole Tmax Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 24 hours postdose
  9. Part 3: Steady-state Omeprazole Area Under The Concentration-time Curve From Time 0 To The 24-hour Time Point (AUC0-24) Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state DanicopanTime frame: Up to 24 hours postdose
  10. Part 3: Steady-state Danicopan Cmax Alone Versus In The Presence Of Multiple-dose OmeprazoleTime frame: Up to 8 hours postdose
  11. Part 3: Steady-state Danicopan Tmax Alone Versus In The Presence Of Multiple-dose OmeprazoleTime frame: Up to 8 hours postdose
  12. Part 3: Steady-state Danicopan Area Under The Concentration-time Curve From Time 0 To The 8-hour Time Point (AUC0-8) Alone Versus In The Presence Of Multiple-dose OmeprazoleTime frame: Up to 8 hours postdose
  13. Part 3: Steady-state Danicopan Cmax Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/SimethiconeTime frame: Up to 8 hours postdose
  14. Part 3: Steady-state Danicopan Tmax Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/SimethiconeTime frame: Up to 8 hours postdose
  15. Part 3: Steady-state Danicopan AUC0-8 Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/SimethiconeTime frame: Up to 8 hours postdose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.